Clinical Trial Search

Primary: Proportion of Patients Who Are Alive and Progression-free for at Least 12 Months After Study Entry in Patients With Newly Diagnosed Stage III or IV Clear Cell Ovarian…

Primary: Number of Participants Who Experience at Least 1 Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE) — 6; 3; 2; 1 participants

Primary: To Estimate the Change in Bleeding Category (Surgical Field Improvement) as Measured on a Six-point Scale, Measured From 0 (Best Case) to 5 (Worst Case). — 2.17; 2.04…

Primary: Proportion of Participants Confirmed as Improvement Responders for Primary Multicomponent Endpoint — 0.516; 0.511; 0.656; 0.688 proportion of participants — p=0.9584

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 97.3 percentage of participants

Primary: Duration of Intraoral Local Anesthesia — 132.48; 173.27; 182.09; 195.35 minutes — p=<0.05

Primary: 2-year Progression-free Survival in Early Disease Participants — 79.5 percentage of participants

Primary: Pulmonary Vein Reconnection — 10; 10 Participants — p=<0.01

Primary: The Amount of Peanut Protein Ingested Before An Allergic Reaction is Observed During the Double-blind, Placebo Controlled Food Challenge (DBPCFC) After Completing…

Primary: Tumor Response Rate Measured by the Response Evaluation Criteria in Solid Tumors (RECIST) — 0; 0; 0; 8 participants

Primary: Intracardiac and Transesophageal Echo Results — 71; 69; 4; 1 participants

Primary: Change From Baseline to Day 10 in 24-hour Mean Ambulatory Systolic Blood Pressure (SBP) — -0.47; -2.49 mmHg

Primary: Number of Participants With Dose Limiting Toxicities (DLT): Part 1 Phase 1 — 1; 1 Participants

Primary: Summed Pain Intensity Difference Over the First 48 Hours (SPID48). — -2328.2; -548.90 units on a scale — p=0.0180

Primary: Mean Change From Baseline in Daily Reflective Total Nasal Symptom Scores (rTNSS) — -2.11; -2.01 Score on a scale — p=0.604